RASGRF1 and liver cancer: Our findings suggest that THY-10A62 (15mg/kg) suppresses FAK (PTK2) protein phosphorylation and expression in mice while potentially upregulating BAD protein phosphorylation through FAK/BRAF pathway to promote tumor cell apoptosis, through FAK/AKT pathway to inhibit tumor motility or through FAK/RASGRF1/Actin pathway to inhibit tumor cell proliferation, thus exerting the anti-liver cancer effect.